CMEOF (Creo Medical Group) Quality Rank


CMEOF Creo Medical Group PLC CMEOF
53 GF Score
Price $0.20
GF Value $0.24
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Creo Medical Group Quality Rank Related Terms

CMEOF
53GF Score
Creo Medical Group PLC CMEOF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.20 is trading 16.7% below its estimated GF Value™ of $0.24.

Key valuation signals for CMEOF:

  • Quality Rank:
  • GF Value™: $0.24 vs. price of $0.20 (16.7% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score

Get the complete analysis for CMEOF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.24
GF Value